[44]SCC12 CatsPS: HPD, 1–5 mg/mg, iv
Light: LED, 300 J/cm2, 630 nm, 1 session

Variable tumor responses (complete, partial and no response)

Tumors localized in the pinna and those highly invasive of the nose and nasal planum presented no response

[101]SCC4 DogsPS: HPD, 5 mg/kg, iv
Light: Argon laser, 293–900 J/cm2, 631 nm, 1–3 sessions[101]Circumanal gland carcinoma1 DogPS: HPD, 5 mg/kg, iv
Light: Argon laser, 144–400 J/cm2, 631 nm, 1 session[79]SCC1 DogPS: HPD, 2.5 mg/kg, iv
Light: Argon laser, 348 J/cm2, 631 nm, 1 session[79]Adenocarcinoma, oral cavity1 DogPS: HPD, 2.5 mg/kg, iv
Light: Argon laser, 100 J/cm2, 631 nm, 1 session[79]SCC, gastric mucosa1 DogPS: HPD, 2.5 mg/kg, iv
Light: Argon laser, 240 J/cm2, 631 nm, 1 session[102]Esophageal SCC1 DogPS: Porfimer sodium, 2.7 mg/kg, iv
Light: Argon laser, 200–250 J/cm3, 630 nm, 3 sessions

Tumor size reduction

Patient returned to oral feeding

Nine months after treatment, marked local invasiveness and regional lymph node metastasis were seen

[82]Lung carcinoma3 DogsPS: Porfimer sodium, 2 mg/kg, oral
Light: Diode laser, 200 J/cm, 630 nm, 1 session

Tolerable and manageable side effects

100% success rate

Tumors presented coagulative central necrosis, arterial thrombosis, and the presence of few inflammatory cells

[86]SCC11 CatsPS: 5-ALA, cream 20%, topical
Light: LED, 12 J/cm2, 635 nm, 1 session

85% complete response rate with a single PDT treatment

Recurrence in 63.6% of cases

Recurrence occurred after 19 to 56 weeks

[85]SCC55 CatsPS: 5-ALA, cream 20%, topical
Light: LED, 12 J/cm2, 635 nm, 1 session

Temporary mild local adverse effects after treatment

96% of animals responded to treatment (11% presented partial and 85% complete response)

Of those with complete response, recurrence occurred in 51% after a median time of 157 days

22 cats received repeated PDT treatments, and after a median time of 1146 days, 45% were alive and disease free, and 33% had tumor recurrence

[95]Transitional cell carcinoma6 DogsPS: 5-ALA, 60 mg/kg, oral
Light: Diode laser, 100 J/cm−2, 635 nm, 1–3 sessions[71]Transitional cell carcinoma2 DogsPS: 5-ALA, 40 mg/kg, oral
Light: LED, 300 J/cm2, 635 nm, 3 sessions; Diode laser, 270 J/cm2, 630 nm, 15 sessions[71]Adenocarcinoma2 DogsPS: 5-ALA, 40 mg/kg, oral
Light: Diode laser, 270 J/cm2, 700 J/cm, 630 nm, 15–19 sessions[71]Sebaceous gland carcinoma1 CatPS: 5-ALA, 40 mg/kg, oral
Light: LED, 120 J/cm2, 635 nm, 4 sessions[103]Transitional cell carcinoma of the prostate1 DogPS: 5-ALA, 60 mg/kg
Light: Diode laser, 100 J/cm2, 75 mW/cm2, 635 nm, 1 session[104]Prostate Carcinoma6 DogsPS: 5-ALA, intratumoral
Light: Halogen lamp, 75 J/cm2, 570-670 nm, 1 session[105]SCC4 DogsPS: BPD-MA, 0.5 mg/mg, iv
Light: Diode laser, 40–90 J/cm2, 690 nm, 1 session

PDT used as anti-angiogenic

Tumoral necrosis occurred after a few days

Granulation tissue formed in the surrounding tissues before healing

[106]SCC3 DogsPS: BPD-MA, 0.5 mg/mg, iv
Light: Diode laser, 80–600 J/cm2, 690 nm, 1–2 sessions

Oedema and fistula were observed as side effects

Tumor recurred, and metastasis were observed

[106]Adenocarcinoma3 DogsPS: BPD-MA, 0.5 mg/mg, iv
Light: Diode laser, 50–350 J/cm2, 200–300 J/cm, 690 nm, 1–2 sessions[107]Basal cell carcinoma1 CatPS: PAD-S31, 15 mg/kg, iv
Light: Argon laser, 150 J/cm2, 670 nm, 3 sessions[108]Intranasal carcinoma3 DogsPS: Talaporfin sodium, 5.0 mg/kg, iv
Light: Diode laser, 100 J/cm2, 665 nm, 1–3 sessions[96]SCC8 CatsPS: EtNBS, 5 mg/kg, iv
Light: Diode laser, 400–800 J/cm2, 652 nm, 1–2 sessions

Minimal systemic toxicity

Minor response in two sublingual SCCs

Four complete responses at long-term evaluation and two partial responses in six facial SCCs

[96]SCC2 DogsPS: EtNBS, 2.0–2.5 mg/kg, iv
Light: Diode laser, 303–400 J/cm2, 652 nm, 1–2 sessions[109]Intranasal carcinoma2 DogsPS: HPPH, 0.3 mg/kg, iv
Light: Potassium titanyl phosphate–pumped dye laser, 100 J/cm2, 665 nm, 1 session[109]Intranasal carcinoma1 CatPS: HPPH, 0.3 mg/kg, iv
Light: Potassium titanyl phosphate–pumped dye laser, 100 J/cm2, 665 nm, 1 session[110]SCC (facial lesions)51 CatsPS: HPPH, 0.3 mg/kg, iv
Light: Argon laser, 100 J/cm2, 665 nm, 1–3 sessions

No systemic toxicity

Complete response in T1a tumors

Partial response in T1b (56%) and T2b (18%) tumors

100% one-year local control rate for T1a and 53% for T1b tumors

[111]SCC3 DogsPS: HPPH, 0.15 mg/mg, iv
Light: LED, 100 J/cm2, 665 nm, 1 session[111]Adenocarcinoma apocrine gland1 DogPS: HPPH, 0.15 mg/mg, iv
Light: LED, 100 J/cm2, 665 nm, 1 session[111]SCC3 CatsPS: HPPH, 0.15 mg/mg, iv
Light: LED, 100 J/cm2, 665 nm, 1 session[112]Oral SCC11 DogsPS: HPPH, 0.3 mg/kg, iv
Light: Argon laser, 100 J/cm2, 665 nm, 1 session[113]SCC8 CatsPS: CASPc, 1 mg/kg, iv
Light: Argon laser, 100–150 J/cm2, 675 nm, 1–2 sessions

No systemic toxicity

No skin photosensitization

Overall treatment response similar to surgery, hyperthermia, and cryotherapy

[113]Carcinoma in situ3 CatsPS: CASPc, 1.0 mg/kg, iv
Light: Argon laser, 100 J/cm2, 675 nm, 1–2 sessions[83]SCC15 CatsPS: CASPc, 1 mg/kg, iv
Light: Argon laser, 50–150 J/cm2, 675 nm, 1 session

At three months post-treatment, 20% of cats presented no response, 7.5% partial response, and 67% complete therapeutic response

7.5% presented tumor recurrence

[114]Cutaneous SCC10 CatsPS: CASPc, 1.0 mg/kg, iv
Light: Argon laser, 100–200 J/cm2, 675 nm, 1 session[84]SCC6 DogsPS: ZnPcS4, 1–4 mg/mg, iv
Light: Diode laser, 100 J/cm2, 675 ± 0.2 nm, 1 session[93]SCC18 CatsPS: Liposomal mTHPC, 0.15 mg/mg, iv
Light: Diode laser, 10 J/cm2, 652 nm, 1 session

100% complete response rate

75% overall control rate at 1-year

20% tumor recurrence (median time to recurrence of 173 days)

[18]SCC38 CatsPS: Liposomal mTHPC, 0.15 mg/mg, iv
Light: Diode laser, 10–20 J/cm2, 652 nm, 1 session

84% response rate (61% complete response and 22% partial response)

Mean disease-free period of 35 months

Median survival period of 40 months

[115]SCC10 CatsPS: Liposomal and lipophilic mTHPC, 0.15 mg/mg, iv
Light: Diode laser, 10 J/cm2, 652 nm, 1 session[116]SCC6 CatsPS: Liposomal and lipophilic mTHPC, 0.15 mg/mg, iv
Light: Diode laser, 10 J/cm2, 652 nm, 1 session[117]Adenocarcinoma3 DogsPS: AO, 1 μg/mL, tumor bed
Light: Xenon light, 20.7 mW/cm2, 400–700 nm, 1 session[117]Carcinoma transitional1 DogsPS: AO, 1 μg/mL, tumor bed and 0.1 mg/kg, iv
Light: Xenon light, 20.7 mW/cm2, 400–700 nm, 1 session[117]Carcinoma undifferentiated1 DogsPS: AO, 1 μg/mL, tumor bed
Light: Xenon light, 20.7 mW/cm2, 400–700 nm, 1 session[118]Intranasal carcinoma14 DogsPS: AO, 1 μg/mL, tumor bed
Light: Xenon light, 20.7 mW/cm2, 400–700 nm, 1 session[60]Adenocarcinomas14 DogsPS: AO, 1 μg/mL, tumor bed
Light: Xenon light, 20.7 mW/cm2, 400–700 nm, 1 session[60]Transitional cell carcinomas10 DogsPS: AO, 1 μg/mL, tumor bed
Light: Xenon light, 20.7 mW/cm2, 400–700 nm, 1 session[60]SCC2 DogsPS: AO, 1 μg/mL, tumor bed
Light: Xenon light, 20.7 mW/cm2, 400–700 nm, 1 session[60]Adenosquamous carcinomas2 DogsPS: AO, 1 μg/mL, tumor bed
Light: Xenon light, 20.7 mW/cm2, 400–700 nm, 1 session[60]Carcinoma3 DogsPS: AO, 1 μg/mL, tumor bed
Light: Xenon light, 20.7 mW/cm2, 400–700 nm, 1 session[60]Undifferentiated adenocarcinomas1 DogPS: AO, 1 μg/mL, tumor bed
Light: Xenon light, 20.7 mW/cm2, 400–700 nm, 1 session[60]Undifferentiated carcinomas1 DogPS: AO, 1 μg/mL, tumor bed
Light: Xenon light, 20.7 mW/cm2, 400–700 nm, 1 session